Published in PLoS One on October 20, 2016
Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw (2010) 38.65
ROCR: visualizing classifier performance in R. Bioinformatics (2005) 19.60
Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res (1996) 3.73
A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol (1990) 3.58
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
T and Tn, general carcinoma autoantigens. Science (1984) 3.10
New tumor markers: CA125 and beyond. Int J Gynecol Cancer (2005) 2.92
Sialic acids in human health and disease. Trends Mol Med (2008) 2.61
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal (2008) 2.05
Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer (2011) 1.84
Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res (2010) 1.79
Glycans as cancer biomarkers. Biochim Biophys Acta (2011) 1.66
Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol (2009) 1.56
Cell surface protein glycosylation in cancer. Proteomics (2014) 1.42
Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst (2011) 1.39
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol (2011) 1.37
Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer. Proc Natl Acad Sci U S A (2008) 1.33
ABO blood group and related antigens, natural antibodies and transplantation. Tissue Antigens (2006) 1.32
Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev (2012) 1.32
alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res (2008) 1.27
Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res (2011) 1.25
Challenges for chemotherapy in ovarian cancer. Ann Oncol (2006) 1.20
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev (2009) 1.16
Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics (2010) 1.16
Natural antibodies and cancer. N Biotechnol (2009) 1.12
Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res (2012) 1.08
Ovarian cancer screening--current status, future directions. Gynecol Oncol (2013) 1.06
In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem (2014) 1.04
Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J Clin Immunol (2014) 1.01
A high-throughput O-glycopeptide discovery platform for seromic profiling. J Proteome Res (2010) 1.00
Analysis of site-specific glycosylation of renal and hepatic γ-glutamyl transpeptidase from normal human tissue. J Biol Chem (2010) 0.98
Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B. Cell Prolif (2002) 0.97
Xenoantigens and xenoantibodies. Xenotransplantation (1998) 0.97
Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther (2013) 0.96
Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies? Biochim Biophys Acta (2012) 0.94
Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies. Glycoconj J (2011) 0.94
Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array. Int J Cancer (2011) 0.92
Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int J Cancer (2014) 0.89
The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med (2015) 0.89
Multiplex suspension array for human anti-carbohydrate antibody profiling. Analyst (2010) 0.87
Printed glycan array: antibodies as probed in undiluted serum and effects of dilution. Glycoconj J (2012) 0.86
Biotinylated multivalent glycoconjugates for surface coating. Methods Mol Biol (2010) 0.85
Natural antibodies to glycans. Biochemistry (Mosc) (2013) 0.85
The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration. Br J Cancer (2014) 0.81
Characterization of anti-Forssman (anti-Fs) antibodies in human sera: their specificity and possible changes in patients with cancer. J Immunol (1979) 0.81
PEGylation of microbead surfaces reduces unspecific antibody binding in glycan-based suspension array. J Immunol Methods (2014) 0.81
Natural human immunoglobulins in cancer immunotherapy. Immunotherapy (2009) 0.80
Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicine. Cancer Lett (2013) 0.80
Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs. Biomark Med (2009) 0.79
Naturally occurring antibodies directed against carbohydrate tumor antigens. Adv Exp Med Biol (2012) 0.79
Monomeric and multimeric blockers of selectins: comparison of in vitro and in vivo activity. Biochemistry (Mosc) (2005) 0.77